Please login to the form below
sitagliptin
This page shows the latest sitagliptin news and features for those working in and with pharma, biotech and healthcare.
FDA’s year-end approvals take annual tally to 46
Merck and Pfizer picked up an FDA approval for SGLT2 inhibitor Steglatro (ertugliflozin) and combinations Steglujan (ertugliflozin and sitagliptin) and Segluromet (ertugliflozin and metformin) for use in adults with type 2
Latest news
-
FDA panel backs CV claims for Novo Nordisk's Victoza
Merck &Co failed to win FDA approval for a similar claim for its DPP-4 inhibitor Januvia (sitagliptin) in April.
-
FDA won't add outcomes data to Januvia label
The US regulator has sent the pharma company a complete response letter for DPP-4 inhibitor Januvia (sitagliptin) and combination product Janumet (sitagliptin plus metformin) - along with extended release formulations - saying
-
Merck & Co and Pfizer take aim at diabetes with trio of new drugs
The marketing applications – filed in the US and EU – cover ertugliflozin as a monotherapy, a fixed-dose combination of ertugliflozin and Januvia (sitagliptin), and a fixed-dose combination of the SGLT2
-
EU clears AZ's FDA-rejected diabetes combination
The heart failure warning is particularly troublesome for AZ as it does not extend to Merck's top-selling DPP-4 inhibitor Januvia (sitagliptin), which is also being combined with SGLT2 ... A clean label suggests that sitagliptin/ertugliflozin will mount
-
AZ, BMS and Boehringer among UK Prix Galien finalists
sitagliptin. Januvia. MSD. Type 2 Diabetes Mellitus. alglucosidase alfa. Myozyme. Sanofi Genzyme.
More from news
Approximately 9 fully matching, plus 97 partially matching documents found.
Latest Intelligence
-
Market dynamics, marketing and analytics
The dotted horizontal line denotes market growth. The vertical dotted line indicates market leadership where Sitagliptin (Januvia) is the clear winner that is no longer growing at the speed of the
-
Interview: Christopher Boulton, AstraZeneca
sitagliptin) and Bristol-Myers Squibb (BMS), the original marketers of diabetes standard metformin under the brand name Glucophage.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Featured jobs
-
Senior Programme Executive
-
Salary TBC
- Senior Medical Writer, Medical Communications, Relocate to Cardi...
-
Excellent Salary
- FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...
-
EXCELLENT DAY RATES AVAILABLE
- Editor – Medical Education Agency – Bucks
-
Salary TBC
- Account Manager – Med Comms – London
-
Salary TBC
- Head of Operations/ BUD, Healthcare PR, London – Excellent leade...
-
Excellent Package
- Senior Account Manager / Account Director
-
Great salary and bebefits
-
Senior Medical Writer
-
Great salary and benefits
- Principal Medical Writer, Medical Communications, Relocate to Ca...
-
Excellent Salary
- Editorial Team Leader or Scientific Director
-
£50, 000 - £55, 000 benefits
- Senior / Principal Regulatory Writer – Home Working - UK or US
-
HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS
-
Senior Medical Writer
-
Great salary and bebefits
- Editor > Senior Editor – Medical Education – London
-
Very competitive with excellent benefits
- Senior Account Manager – Med Comms – Kent
-
Salary TBC
-
Scientific Director
-
Great salary and bebefits
- FREELANCE Account Manager – Creative Healthcare Advertising – Lo...
-
SUPERB DAY RATES AVAILABLE
-
Account Manager, Healthcare PR
-
£40, 000 – £42, 000 great benefits and bonuses
Subscribe to our email news alerts
PMHub
GCI Health
GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...
Latest intelligence
- No incentive for a cure
- The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
- Why heading online for scientific meetings can yield greater HCP engagement
- Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
- The threat of antimicrobial resistance
- Why this issue is such a fundamental challenge...
Quick links
Infographics
